Cover Introduction ProSure Clinical Studies ... - Abbott Nutrition

CoverEffect of oral eicosapentaenoic acid on weight loss in patients withpancreatic cancerWigmore SJ, Barber MD, Ross JA, Tisdale MJ, Fearon KCH Nutr Cancer. 2000;36(2):177-184IntroductionProSureClinical StudiesSupportingPublicationsPatients with unresectable adenocarcinoma of the pancreas wereenrolled in this prospective, single-arm study.Objective:To evaluate the acceptability and effects of oral supplementation withhigh-purity eicosapentaenoic acid (EPA) in weight-losing patients withadvanced pancreatic cancer.Study Design:• Study Population: Patients with unresectableadenocarcinoma of the pancreas (n = 26)• length of Study: 12 weeks• Intervention: Daily EPA supplementation starting at 1 g/dayfor the 1st week and increasing to a maximum of 6 g/day fromweek 4 to the end of the studyOutcomes:• Before supplementation, all patients had been losing weight ata median rate of 2.0 kg/month and had lost a median of 13% oftheir usual body weight.• A median weight gain of 0.5 kg/month (P = 0.0009) was observedafter 4 weeks of supplementation.• There were no significant changes in total body water, and thepercentage of people with an elevated CRP did not increase.Weight changes in pancreatic cancer patients (n = 26)who were given EPAStudy Conclusions:As observed in the 1998 study conducted by Wigmore et al, highlypurified EPA stabilized weight in people with pancreatic cancerand tempered the progression of weight loss. However, increasingthe maximum daily dose of EPA from 2 g to 6 g did not appear toenhance the anticachectic effects.EPA -eicosapentaenoic acid